Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life.

Autor:	Viol Ferreira Lopes MA; Santa Casa de Misericórdia de São Paulo, SP, Brazil. Electronic address: maricyviol@gmail.com., Higashi F; Santa Casa de Misericórdia de São Paulo, SP, Brazil; Germano Clinic, São Paulo, SP, Brazil., Crusoe EQ; Universidade Federal da Bahia (UFBA), BA, Salvador, Brazil., Peres ALM; Germano Clinic, São Paulo, SP, Brazil., Cury P; Germano Clinic, São Paulo, SP, Brazil., Hungria VTM; Santa Casa de Misericórdia de São Paulo, SP, Brazil; Germano Clinic, São Paulo, SP, Brazil.
Jazyk:	angličtina
Zdroj:	Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2023 Apr-Jun; Vol. 45 (2), pp. 259-265. Date of Electronic Publication: 2022 Aug 26.
DOI:	10.1016/j.htct.2022.07.005
Abstrakt:	Introduction: Multiple myeloma is characterized by proliferation of clonal plasma cells. The identification of prognostics factors to identify patient's risk is important. Among the studied factors, it was identified of relevant importance the lactic dehydrogenase. Objectives: To evaluate the impact of the value of DHL in combination with the score ISS in the medium patients overall survival (OS). Methods: It is a retrospective cohort with 252 patients with MM recently-diagnosed that attendance in the institution of the study. Results: To evaluate the association between DHL and ISS, we found 6 new groups to be analyzed: ISS I and normal DHL with medium overall survival not reached, and with DHL loud with medium OS of 69,8 months, ISS II and normal DHL with medium overall survival of 78,8 months and with DHL loud with medium OS of 73,9 months, ISS III and normal DHL with medium overall survival of 46,7 months and with DHL loud with medium OS of 45,5 months. Conclusion: Through the association of ISS I and normal DHL, ISS III and high DHL and others combinations, we build a new score with superior impact prognostic in our population treated in real life. Competing Interests: Conflicts of interest The authors have declared there is no conflict of interest. (Copyright © 2022 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu